Go to JCI Insight
Jci spelled out white on transparent.20160208
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews...
    • Cellular senescence in human disease (Apr 2018)
    • Fibrosis (Jan 2018)
    • Glia and Neurodegeneration (Sep 2017)
    • Transplantation (Jun 2017)
    • Nuclear Receptors (Apr 2017)
    • Metabolism and Inflammation (Jan 2017)
    • Hypoxia and Inflammation (Oct 2016)
    • View all review series...
  • Collections
    • Recently published
    • Commentaries
    • Concise Communication
    • Editorials
    • Opinion
    • Scientific Show Stoppers
    • Top read articles
    • In-Press Preview
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

Jci only white

  • About
  • Editors
  • Consulting Editors
  • For authors
  • Current issue
  • Past issues
  • By specialty
  • Subscribe
  • Alerts
  • Advertise
  • Contact
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • Brief Reports
  • Technical Advances
  • Commentaries
  • Editorials
  • Hindsight
  • Review series
  • Reviews
  • The Attending Physician
  • First Author Perspectives
  • Scientific Show Stoppers
  • Top read articles
  • Concise Communication
Top
  • View PDF Adobe pdf file icon
  • Download citation information
  • Send a letter
  • License information
  • Standard abbreviations
  • Article usage
  • Citations to this article
  • Share this article
  • Need Help? E-mail the JCI
  • Top
  • Abstract
  • Supplemental material
  • Version history
Advertisement

In-Press Preview Research ArticleImmunologyOncology Free access | 10.1172/JCI98509

Imaging activated T cells predicts response to cancer vaccines

Israt S. Alam, Aaron T. Mayer, Idit Sagiv-Barfi, Kezheng Wang, Ophir Vermesh, Debra K. Czerwinski, Emily M. Johnson, Michelle L. James, Ronald Levy, and Sanjiv S. Gambhir

Find articles by S. Alam, I. in: JCI | PubMed | Google Scholar

Find articles by T. Mayer, A. in: JCI | PubMed | Google Scholar

Find articles by Sagiv-Barfi, I. in: JCI | PubMed | Google Scholar

Find articles by Wang, K. in: JCI | PubMed | Google Scholar

Find articles by Vermesh, O. in: JCI | PubMed | Google Scholar

Find articles by K. Czerwinski, D. in: JCI | PubMed | Google Scholar

Find articles by M. Johnson, E. in: JCI | PubMed | Google Scholar

Find articles by L. James, M. in: JCI | PubMed | Google Scholar

Find articles by Levy, R. in: JCI | PubMed | Google Scholar

Find articles by S. Gambhir, S. in: JCI | PubMed | Google Scholar

First published March 29, 2018 - More info

J Clin Invest. https://doi.org/10.1172/JCI98509.
Copyright © 2018, American Society for Clinical Investigation

First published March 29, 2018
Abstract

In situ cancer vaccines are under active clinical investigation due to their reported ability to eradicate both local and disseminated malignancies. Intratumoral vaccine administration is thought to activate a T cell mediated immune response, which begins in the treated tumor and cascades systemically. We describe a positron emission tomography tracer (64Cu-DOTA-AbOX40) that enabled non-invasive and longitudinal imaging of OX40, a cell surface marker of T cell activation. We report the spatiotemporal dynamics of T cell activation following in situ vaccination with CpG oligodeoxynucleotide, in a dual tumor bearing mouse model. We demonstrate that OX40 imaging could predict tumor responses at day 9 post treatment based on tumor tracer uptake at day 2, with higher accuracy than both anatomical and blood-based measurements. These studies provide key insights into global T cell activation following local CpG treatment and indicate that 64Cu-DOTA-AbOX40 is a promising candidate for monitoring clinical cancer immunotherapy strategies.

Supplemental material

View Supplementary Materials and Methods

View Supplementary Figure 1

View Supplementary Figure 2

View Supplementary Figure 3

View Supplementary Figure 4

View Supplementary Figure 5

View Supplementary Figure 6

View Supplementary Figure 7

View Supplementary Figure 8

View Supplementary Figure 9

View Supplementary Movie 1

View Supplementary Movie 2

Version history
  • Version 1 (March 29, 2018): In-Press Preview

Article tools

  • View PDF Adobe pdf file icon
  • Download citation information
  • Send a letter
  • License information
  • Standard abbreviations
  • Article usage
  • Citations to this article
  • Share this article
  • Need Help? E-mail the JCI

Go to:

  • Top
  • Abstract
  • Supplemental material
  • Version history
Advertisement
Advertisement
Follow JCI: Facebook logo white Twitter logo v2 Rss icon
Copyright © 2018 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts